Stocks · News reference
Takeda Pharmaceutical Co (NYSE:TAK) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent ruxolitinib
The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.
The global AI in drug discovery market is projected to grow from USD 2.55 billion in 2025 to USD 31.79 billion by 2035, expanding at a 28.70% CAGR. Lead optimization and oncology applications are driving adoption, with pharmaceutical companies and biotech firms leading investment. Strategic partnerships and funding rounds, including Isomorphic Labs' $600 million raise and Takeda's $1.7 billion collaboration with Iambic Therapeutics, are accelerating market growth.